ATAI Investor Presentation Deck

SUMMARY OWNERSHIP 59.5%¹ PRODUCT PHARMA- COLOGY PRODUCT FEATURES INDICATIONS CURRENT STATUS INTELLECTUAL PROPERTY HIGHLIGHT Ibogaine HCI capsules (DMX-1002), ibogaine is a naturally occurring psychedelic compound isolated from a West African shrub, iboga Opioid mediated, cholinergic, glutamatergic and monoaminergic receptor modulator A single dose of ibogaine may precipitate a rapid withdrawal and long-term abstinence in OUD patients Primary: Opioid Use Disorder Potential: Substance Use Disorder, Post- Traumatic Stress Disorder, Traumatic Brain Injury Phase 1/2 trial initiated Q3 '21 Pending method of treatment claims for OUD for ibogaine, issued method of treatment claims for OUD patients on methadone for noribogaine³ Potential sustained reduction in opioid craving with DMX-1002 single administration A single-dose of ibogaine showed potential for sustained reductions in opioid cravings in 75 opioid- dependent patients PRIOR EVIDENCE IN HUMANS (THIRD PARTY STUDY²) HCQN Subscale 5 0 Pre-dose (N=75) ONGOING PHASE 1/2 TRIAL TREATMENT (MULTIPLE DOSES) + Stage 1: Maximum Tolerated Dose Subject cohort: Recreational opioid users (up to 24 subjects) Discharge (N=74) SAFETY/PK Objective: Dose finding 1 Month (N=37) Emotionality (negative mood state) Compulsivity (lack of confidence in ability to quit) Purposefulness (desire of intent to use) Expectancy (expected positive benefits of drug use) Stage 2: Proof of Concept TREATMENT VS PCB Patient cohort: Opioid dependent patients (approximately 80 subjects) 32 SAFETY/EFFICACY Endpoints: Acute withdrawal, abstinence over 90 days Note: HCQN = Heroin Craving Questionnaire, PTSD = Post-traumatic stress disorder, OUD = Opioid use disorder, PCB = Placebo, PK = Pharmacokinetics. (1) Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of June 30th, 2022. Refers to ownership in DemeRx IB. DemeRx NB ownership is 6.3%, which does not give effect to option to acquire further shares which may increase the ownership to up to 57.1% (2) Mash et al., "Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes" (2018) (3) Noribogaine Intellectual property resides in DemeRx NB

View entire presentation